Corbus CEO to Present at Summit as 240-Patient Phase1b CRB-913 Trial Underway
Corbus CEO Yuval Cohen will join the Emerging Companies panel at the BMO 2026 Metabolic Health Summit in New York on March 24. The company’s CRB-913 CB1 inverse agonist showed rapid weight loss in a 14-day Phase 1a study and enters a 240-patient Phase 1b trial concluding summer 2026.
1. CEO Participation at Metabolic Health Summit
On March 24 in New York, Corbus CEO Yuval Cohen will join the Emerging Companies panel at the BMO 2026 Metabolic Health Summit to discuss next-generation treatments for metabolic disease.
2. CRB-913 Clinical Progress and Timeline
CRB-913, an orally delivered, peripherally restricted CB1 inverse agonist for obesity, achieved potent, rapid weight loss with favorable GI tolerability in a 14-day Phase 1a SAD/MAD study; a 240-patient Phase 1b dose-ranging trial is expected to conclude in summer 2026.
Related News
CRM
Salesforce Faces Competition from Nvidia’s $200B AI CPU, Nasdaq Rally
CRM•
JEPQ
JPMorgan ETF Offers 9.5% Yield with Hidden ELN Counterparty Risk
JEPQ•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
ELF
e.l.f. Beauty Marks 29th Consecutive Sales Growth, Reinvests $58.5M Tariff Refunds
ELF•
VBCF
Vanguard’s BondBuilder ETFs Garner $242M, Join $70B Target Maturity Market
VBCF•
Sources
F